June 17, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is newly reviewing the risk of interstitial lung disease for Pfizer’s breast cancer drug Ibrance (palbociclib) - a move likely to trigger a label change in the near future - according to the...read more